Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy COMMIT Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair dMMR/Microsatellite Instability-High MSI-H Metastatic Colorectal Cancer

Brief Summary

Type:
Colorectal

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT02997228

Study #:
STUDY00141960

Start Date:
Apr 16, 2018

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT02997228

View Complete Trial Details & Eligibility at ClinicalTrials.gov